When was ALPHACAPS acquired by LUXEMPART?

ALPHACAPS was acquired by LUXEMPART in 2023.

How is the data for the ALPHACAPS acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the ALPHACAPS deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://www.luxempart.lu/media/2023/10/Press-Release-Luxempart-alphacaps.pdf

← DATABASE

Home Database Healthcare & PharmaALPHACAPS

10/2023

ALPHACAPS acquired by LUXEMPART

GERMANY Life Sciences / Nutrition & Dietary Supplements REV 1m EUR - 100m EUR

Context

Luxempart acquired a substantial minority stake in Alphacaps GmbH. The deal is meticulously designed to establish a long-term, highly aligned partnership between the historical owners and the incoming financial sponsor. By providing a flexible capital solution, Luxempart injects fresh momentum into the enterprise, perfectly equipping the incumbent management team with the vital strategic backing and resources required to actively execute their ongoing development roadmap. The primary objective of this new alliance is to massively accelerate the target's expansion within the fast-growing European nutritional supplements market.

ALPHACAPS, which reported an EBITDA margin of in 2023, is valued in this transaction at an EV/EBITDA multiple of , a level to compare with the average currently observed in the Healthcare & Pharma sector (15.3x).

-> Deep-dive in Healthcare & Pharma market trends

Target

Alphacaps is a leading full-service contract developer and manufacturer specifically dedicated to the nutritional and food supplements industry. Benefiting from deep sector know-how and state-of-the-art production machinery, the enterprise holds all the required certifications to manufacture a comprehensive variety of high-quality formulations and formats. The firm operates within a rapidly expanding market and heavily differentiates itself through its uncompromising product quality, relentless focus on customer satisfaction, and exceptional agility in rapidly adapting to ever-changing consumer trends. Driven by robust operational fundamentals, the company is ideally positioned to capitalize on structural market growth.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2023

2022

Similar deals in Life Sciences

List of similar M&A transactions (Date, Acquirer, Target, Country, Sub-sector)
Date	Acquirer	Target	Country	Sector
11/2023	AMETEK	PARAGON MEDICAL	UNITED STATES	Medical Devices
11/2023	ANJAC BEAUTY & HEALTH	STEPHID	FRANCE	CDMO
10/2023	RESONETICS	NITINOL BUSINESS	UNITED STATES	Medical Devices
08/2023	ATHOS CONSORTIUM	SCHÜLKE	GERMANY	Medical Consumables
08/2023	OAKLEY CAPITAL INVESTMENTS	LIBERTY DENTAL GROUP	GERMANY	Implants & Prosthetics
08/2023	CARL ZEISS MEDITEC	D.O.R.C. (DUTCH OPHTHALMIC RESEARCH CENTER)	NETHERLANDS	Medical Devices
07/2023	EQT PARTNERS / ADIA	DECHRA PHARMACEUTICALS	UNITED KINGDOM	Pharma & Biotech
07/2023	LAUXERA	ORGANOX	UNITED KINGDOM	Medical Devices
07/2023	ELOS MEDTECH	KLINGEL MEDICAL GROUP	GERMANY	Implants & Prosthetics
06/2023	NOVO NORDISK	BIOCORP	FRANCE	Medical Devices

REFERENCES

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of ALPHACAPS by LUXEMPART are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

Press release: view release

Target: alphacaps

Acquirer: luxempart